Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

SMT19969 in-vitro data proves promising
November 2015
SHARING OPTIONS:

OXFORD, U.K.—The 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, held last month in San Diego, saw Summit Therapeutics present new preclinical data on SMT19969, a novel, selective oral antibiotic for the treatment of C. difficile infection. The compound demonstrated high potency against 107 clinical isolates of C. difficile (chosen to maximize the diversity of their resistance to common antibiotics) as well as a low resistance development profile.
 
“These new data further illustrate the promise of SMT19969 as a differentiated antibiotic to treat CDI and, through its selective antibiotic profile, potential to leave the healthy gut microbiome unharmed, and so address the key clinical issue of disease recurrence,” said Summit CEO Glyn Edwards. “It is an exciting time in the development of SMT19969 as we look forward to reporting top-line data from our Phase 2 proof-of-concept trial during the fourth quarter of this year.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.